Author: Editor

Jean-Jacques Kiladjian, MD, PhD from the Saint-Louis Hospital & Paris Diderot University, Paris, France provides an overview of the COMFORT-II clinical trial, a Phase III study comparing ruxolitinib with best available therapy in patients with intermediate to high-risk myelofibrosis. Ruxolitinib improved the spleen response and reduced the symptoms of myelofibrosis, leading to an increase in quality of life that could be maintained over several years. Patients who received best available therapy and then switched to ruxolitinib after the primary end point was achieved, they were still able to experience the benefits of the drug.

Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA talks about the use of elotuzumab for the treatment of multiple myeloma, in the relapsed/refractory setting or in combination with other drugs, such as pomalidomide. Elotuzumab is an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), a specific receptor in the natural-killer cell population.

Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY discusses common side-effects observed in the Phase III clinical trial of idelalisib plus bendamustine and rituximab in rlapsed/refractory chronic lymphocytic leukemia (CLL). Idelalisib is associated with colitis, pneumonitis, elevated transaminases, increased risk of febrile neutropenia, but these did not affect overall survival (OS). Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando. FL.

Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the 3-year update presented at the American Society of Hematology (ASH) 2015 Annual Meeting, on the ELOQUENT-2 clinical trial of elotuzumab in combination with lenalidomide and dex­a­meth­a­sone in multiple myeloma. The study demonstrated a sustained progression-free survival (PFS) benefit to patients in the elotuzumab arm, when compared to placebo in relapsed/refractory myeloma.

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Roy Denis-Claude, MD, from Maisonneuve-Rosemont Hospital and Montreal University, Montreal, QC, Canada, discusses the results of an open-label, multi-center phase 2 clinical trial, which showed donor lymphocytes depleted of alloreactive T cells (ATIR101) reduced transplant-related mortality and improved overall survival in haploidentical hematopoietic stem cell transplantation (HSCT) for patients with high-risk acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL), using an immunosuppressant-free transplant regimen.

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, discusses the upcoming Myeloma 2016 meeting, which will be held in Boston in April 2016. The meeting provides a platform for a high-level discussion for globally recognised clinicians and researchers in the field of multiple myeloma, and topics will include genomics, minimal residual disease, immuno-oncology and new therapeutic targets.

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, discusses data from a phase 1 clinical trial investigating an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, summarises recently approved treatment options for patients with relapsed multiple myeloma, including proteasome inhibitors, carfilzomib and ixazomib; histone deacetylase (HDAC) inhibitor, panobinostat; and monoclonal antibodies, CS1-targeting elotuzumab and CD38-targeting daratumumab.

Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ talks about the new therapies in multiple myeloma, such as ixazomib, elotuzumab, daratumumab and Isatuximab. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.

Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the new methods used to measure treatment response in multiple myeloma (MM). Minimum residual disease (MRD) has been the main method in recent years, and it’s the next frontier in MM. The main tools used are multicolour flow cytometry and next-generation sequencing. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.

Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a clinical trial (IFM 2013-04) of bortezomib plus lenalidomide and dexamethasone (LEN/DEX) as the primary treatment for multiple myeloma, compared to induction therapy followed by transplant consolidation. In summary, the transplant adds to the care of myeloma patients and Dr Fonseca believes it will continue to be the main treatment used for multiple myeloma until new agents come along. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.

Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a clinicogenetic risk model risk model called m7-FLIPI for the identification of patients with early disease progression of follicular lymphoma after first-line immunotherapy. The m7-FLIPI identifies a series of genes associated with improved/reduced prognosis, information that can be added to the standard FLIPI model that identifies a group of high-risk follicular lymphoma patients. The results of a study to investigate the predictive utility of m7-FLIPI was presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando. FL.

Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a Phase III clinical trial of idelalisib plus bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. The study included 416 patients, with 207 patients in the idelalisib plus bendamustine and rituximab arm and 209 in the bendamustine and rituximab plus placebo arm. The patients were treated with bendamustine and rituximab for 6 months, then idelalisib or placebo until progression. The primary endpoint was progression-free survival (PFS), which was 11.1 months for the placebo arm and 23.1 months for the idelalisib arm,…

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s National Medical Center, Washington, DC, discusses the development of a protocol for the generation of single T-cell lines that simultaneously target a range of tumor-associated antigens that are frequently expressed in tumours of individuals with Hodgkin lymphoma or non-Hodgkin lymphoma, including PRAME, SSX2, MAGEA4, NY-ESO-1 and Survivin.

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s National Medical Center, Washington, DC, discusses the initial analysis of a phase 1 dose escalation study of activated autologous CD30-specific chimeric antigen receptors (CAR) T cells infused in patients with relapsed or refractory CD30-positive Hodgkin lymphoma or non-Hodgkin lymphoma.

Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a few new drugs presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL, in the fields of chronic lymphocytic leukemia (CLL) and lymphoma. Dr Zelenetz talks about venetoclax (ABT-199), a BH3 mimetic used as front-line therapy of CLL. As for lymphoma, Dr Zelenetz draws attention to cell-free DNA studies that can provide additional information at diagnosis or help manage treatment and progression of the disease.

Patient Power founder Andrew Schorr visits with Dr. Michael Keating of MD Anderson Cancer Center to ask audience questions about repeat genetic testing. Dr. Keating discusses which tests are essential, when to test again, and whether every CLL patient should receive the same standard of care from the start. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Multiple myeloma expert Dr. Robert Orlowski responds to a question from a Patient Power community member related to access to newly approved treatments for smoldering myeloma patients. Listen as Dr. Orlowski provides an explanation of smoldering myeloma, including the current standard of care, and goes on to discuss possible with new therapies as well as the ins and outs of participating in a clinical trial. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Can we interrupt the fibrotic process? MPN expert Dr. Srdan Verstovsek of MD Anderson Cancer Center explains PRM-151, and how this anti-fibrotic therapy is being used to improve the quality of life for patients living with a myeloproliferative neoplasm (MPN). Dr. Verstovsek ends this conversation with these words, With good control.it appears to be making people live longer. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Which CLL patients benefit most from chemotherapy? CLL expert Dr. Nicole Lamanna explains the various therapeutic agents currently in use, who they are for and why. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Francesco Annibale d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark talks about the Nordic Lymphoma Group (NLG) study on the addition of etoposide to CHOP in adult anaplastic large cell lymphoma patients. Dr d’Amore discusses how the addition of etoposide improves the outcome of paients, as demonstrated by the Phase II clinical trial published in 2012 on the use of CHOEP bi-weekly followed by autologous transplant consolidation in young patients. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, summarises data on emerging treatment options for patients with multiple myeloma. In newly diagnosed patients, highlights include results from IFM/DFCI 2009, a phase 3 clinical trial investigating autologous transplantation; IFM 2013-04, a phase 3 clinical trial of bortezomib, thalidomide and dexamethasone (VTD) versus bortezomib, cyclophosphamide and dexamethasone (VCD); and SWOG S0777, a phase 3 clinical trial of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone. In relapsed/refractory patients, promising results were observed in trials of new daratumumab-…

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, discusses the final analysis of overall survival from Panorama 1, a phase 3 clinical trial that evaluated panobinostat, a histone deacetylase inhibitor, plus bortezomib, a proteasome inhibitor, and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.

Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of lenalidomide/dexamethasone with/without elotuzumab in patients with relapsed/refractory multiple myeloma (MM). In previous trials, the combination was very active with over 80% response rate. This Phase III trial led to the approval of the elotuzumab in the USA, and demonstrated a 30% improvement in duration of remission, a higher overall response, and the combination also showed activity in high-risk MM patients, in particular the ones with 17p and (4;14) translocation. These results were presented at the American Society of Hematology (ASH)…

A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Bernard M Y Cheung, MA, MB BChir (Cantab), PhD (Cantab), MRCP (UK), FRCP (Edin), FRCP (Lond), FCP, FHKCP, FHKAM (Medicine), from The University of Hong Kong, Hong Kong, reviews the efficacy and safety of biosimilars, including the concerns and approval process associated with their use. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Claire Harrison of the Guy’s and St. Thomas Hospital in London, UK, talks about how in the UK, clinicians have used the Obstetrics Surveillance System (UKOSS) to collect information on pregnant women with certain conditions, including MPNs. This as served a variety of purposes, it has raised awareness in among Obstetricians and Gynaecologists, and it showed that 70% of pregnancies with MPN are successful without risk for the mother and baby. However, this survey also showed an increased risk of early miscarriage and late pregnancy events (for example, pre-eclampsia, small-for-dates babies, early deliveries, and babies with low Apgar scores). Dr…

Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about the molecular architecture of myeloproliferative neoplasms (MPN), it’s implication for diagnosis and response to treatment and data supporting this presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. Dr Harrison discusses the database created by the Florence group (Alessandro Vannucchi) and Mayo Clinic (Ayalew Tefferi), which has shown that a significant proportion of polycythemia vera and essential thrombocythemia (ET) have additional mutations that might impact on prognosis. Two groups (Andreas Reiter & Animesh Pardanani, and the Mayo Clinic group) also…

Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about panobinostat (LBH589), commonly used for the treatment of multiple myeloma, which is now being assessed in myelofibrosis (MF). Panobinostat in combination with ruxolitinib, has been shown to be efficacious and safe for the treatment of myelofibrosis. Other important markers also demonstrated the promising effects of this combinations, such as a 35% reduction in spleen volume and early delivery of changes in bone marrow morphology. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.

Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, gives an overview of the latest results of the COMFORT-II clinical trial. This is a Phase 3 trial comparing the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF). At the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, it was shown that after 5 years of the study 50 patients continued receiving ruxolitinib, the spleen response rate plateaued at approx. 50% and there was a 33% prolongation of survival for patients who received ruxolitinib, which increases to 56% when using the rank…

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS, MRCP(UK), FRCP(Edin), FHKCP, FHKAM (Medicine), from The University of Hong Kong, Hong Kong, explains the clinical relevance of promising molecular targets, including alterations affecting the ESR1 gene and the PI3K signalling pathway, in the development of targeted therapies for patients with metastatic breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50 ADCs to be clinically evaluated in ongoing clinical research programs. While some of the trial results have indeed been impressive, some of the results have been mixed. At a time when some may worry about a high rate of attrition, researchers have correctly pointed out that a high rate of attrition in phase I and II means that only the best trial drugs advance to phase III trials and beyond. In reviewing the cause of failure…

Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the current treatment landscape for high-risk multiple myeloma (MM) patients and what the next steps should be. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc Twitter: https://twitter.com/VJHemOnc

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ talks about new drugs being used for the treatment of multiple myeloma (MM), and where they fit in the current treatment landscape. He discusses how drugs like elotuzumab can be used in the early relapsed setting, whilst daratumumab is more suitbale for 3rd line therapy. He also talks about anit-CD38 therapies being used much earlier, perhaps even as front-line therapy or in combination with other drugs. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc…

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of ixazumib, the first oral proteosome inhibitor to be approved for the treatment of multiple myeloma (MM). The clinical trial assessed the effects and safety of different doses of ixazumib, which showed to have considerable single-agent activity in the MM setting. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc Twitter: https://twitter.com/VJHemOnc

Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR provides an overview of the drugs recently approved for the treatment multiple myeloma (MM), and for which the data has been presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. These include daratumumab, an anti-CD38 monoclonal antibody; ixazomib, the first oral proteasome inhibitor; and elotuzumab, a monoclonal antibody targeting signalling lymphocytic activation molecule F7 (SLAMF7).

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA discusses the highlights of the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. Dr Abramson focuses on the negative presented at ASH 2015, in particular the Pyramid clinical trial that assessed the addition of bortozemib to R-CHOP in diffuse large cell lymphoma (DLBCL), the CALGB-50403 study of bortozemib following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL), and the Lumiere trial of alisertib in relapsed/refractory peripheral T-cell lymphoma (PTCL).

Starting in February 2016, ADC Review / Journal of Antibody-drug Conjugates will offer select (video) interviews with KOLs (Key Opinion Leaders) and experts in the field of ADCs as well as Targeted and Personalized Medicine. This video is one of the intro/leaders used for our interview series. For more information about these interviews or inquiries about how to participate, please contact us at info@inpressmediagroup.com ADC Review / Journal of Antibody-drug Conjugates – http://www.adcreview.com © 2016 InPress Media Group, LLC

Fresh from the 2015 American Society of Hematology (ASH) conference, Dr. Michael Mauro of Memorial Sloan Kettering Cancer Center delves deeply into the world of CML, covering improved treatments and outcomes. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Where do we stand with CAR-T therapy? Could checkpoint inhibitors apply in CLL? CLL expert Dr. William Wierda, from the 2015 American Society of Hematology (ASH) meeting, shares his insights into this exploding field of research. Dr. Wierda explains developing immunotherapy options, including CAR T-cell therapies, which he feels hold the most hope as a curative strategy for CLL.CAR-T Cell Therapy is the next step to cure patients with CLL. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Myeloma expert Dr. Robert Orlowski answers more Ask the Expert questions, this one from Susan: What effect will newly approved drugs, such as daratumamab and ixazomib have on a patient when Revlimid maintenance is no longer effective? Dr. Orlowski gives a detailed answer, including a newer drug, isatuximab, that he says, looks like an active and exciting drug. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At a recent MPN town meeting, MPN experts Dr. Srdan Verstovsek and Dr. Naval Daver from MD Anderson Cancer Center and Dr. Rami Komrokji from Moffitt Cancer discussed treatment considerations for myelofibrosis patients prior to stem cell transplant. Each of the experts shares their perspective on how genetic testing shapes treatment choices, how age affects the decision, and why or why not a particular patient makes a good candidate for transplant. Watch to learn more about why this is an individualized decision for each patient. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info…

Watch an in-depth discussion on emerging immunotherapy approaches for advanced prostate cancer with MD Anderson Cancer Center experts, Drs. Sumit Subudhi and Jeri Kim. Learn about treatments including experimental vaccine treatments and checkpoint inhibitors/immune modulators. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Francesco Annibale d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark provides an overview of the LUMIERE clinical trial of alisertib (MLN8237), an Aurora A kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. When compared to standard of care, such as romidepsin, pralatrexate and gemcitabine, there was no difference in terms of efficacy. However, Dr D’Amore discusses that this clinical was a great achievement in a field of rare diseases such as T-cell lymphomas.

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of a bromodomain and extra-terminal motif (BET) inhibitor for the treatment of non-Hodgkin lymphoma in a first in-human Phase I study.

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib.

Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 965 of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of the multi-centre prospective Phase II study of Dose-Adjusted EPOCH-R for Burkitt Lymphoma.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD, PhD, from the University of Valencia, Valencia, Spain, discusses topics of his highlight session at the congress that summarised research highlights in the management of patients with ovarian cancer in 2015, including the treatment of relapsed ovarian cancer and optimisation of the use of poly(ADP-ribose) polymerase (PARP) inhibitors. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Atsushi Ohtsu, MD, PhD, from National Cancer Center, Kashiwa, Japan, reviews promising approaches for the treatment of patients with gastrointestinal cancer, including molecular targeted therapies and clinical studies of anti-PD-1 antibodies, such as pembrolizumab, for advanced gastric or gastroesophageal junction adenocarcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD, PhD, from the University of Valencia, Valencia, Spain, explains the approach to case study sessions at the congress, which are guided by expert-reviewed and evidence-based ESMO guidelines and aim to promote the international exchange of expertise between Asian and European oncologists. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the clinical development of immune checkpoint inhibitors, including pembrolizumab, an anti-PD-1 antibody, and durvalumab, an anti-PD-L1 antibody, for the treatment of patients with head and neck cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses subgroup analyses and patient-reported outcomes from CheckMate 057, a phase 3, randomised clinical trial that was designed to compare nivolumab, an antiPD-1 antibody, with docetaxel for the treatment of patients with advanced non-squamous non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses a phase 1b clinical trial that was designed to evaluate the safety and antitumour activity of durvalumab, an anti-PD-L1 antibody, combined with tremelimumab, a CTLA-4 antibody, for the treatment of patients with stage III or IV non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the subgroup and biomarker analysis of LUX-H&N1, a phase 3 clinical trial comparing second-line afatinib, an ErbB family blocker, with methotrexate for the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses interim results from KEYNOTE-028, a phase 1b clinical trial that was designed to evaluate the antitumour activity and safety of pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with PD-L1-positive nasopharyngeal carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Fatima Cardoso, MD, from Champalimaud Cancer Centre, Lisbon, Portugal, discusses the implementation of ESMO guidelines on the treatment of metastatic HER2-positive breast cancer in a case study presentation, including the use of the antibody-drug conjugate, T-DM1, and the anti-HER2 antibody, pertuzumab, in different settings of treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Peter Hersey, MD, PhD, from the Melanoma Institute Australia, Sydney, Australia, discusses the opportunities and challenges of promising immunotherapeutic approaches for the treatment of patients with melanoma, including immune checkpoint inhibitors that target pathways related to T-cell activity. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ, provides an overview of the session “Social Media for the Hematologist” held at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. In this session, it was discussed how social media has become a part of medical practice, research, education, and the value of these tools and how to use them effectively.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress President, Rolf A. Stahel, MD, from the University Hospital Zurich, Zurich, Switzerland, explains that the ESMO Asia Congress provides an opportunity for Asian and European oncologists to come together to promote an exchange of expertise, and highlights the access of new medicines as a global challenge. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress President, Rolf A. Stahel, MD, from the University Hospital Zurich, Zurich, Switzerland, provides an overview of approaches that aim to improve patient access to new cancer medicines, including the ESMO Magnitude of Clinical Benefit Scale, which is a validated approach to stratify the magnitude of clinical benefit for cancer medicines. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses an evaluation of overall health status in patients with advanced squamous non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 antibody, or docetaxel in CheckMate 017; and subgroup analyses and patient reported outcomes in patients with advanced non-squamous NSCLC treated with nivolumab or docetaxel in CheckMate 057. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Recently, there have been numerous advances in the biological understanding of ovarian cancer. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann, BSc, MD, FRCP, from UCL Cancer Institute and UCL Hospitals, London UK, discusses the therapeutic development and impact of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, for the management of patients with BRCA-related ovarian cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD, from Gustave Roussy, Villejuif, France, explains that recent developments in the treatment of castrate-resistant prostate cancer have improved overall survival for patients, and now, optimal sequencing of new treatment agents and approaches, such as abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223 and sipuleucel-T, is the next challenge. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Richard A. Van Etten, MD of UC Irvine Health Chao Family gives an update on Chronic Myeloid Leukemia using data from ASH at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Susan OBrien, MD of UC Irvine Health Chao Family gives an update of Chronic Lymphocytic Leukemia with data from ASH 2015 at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Kanwarpal S. Kahlon , MD of UC Irvine Health Chao Family gives an Update on Multiple Myeloma at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Deepa Jeyakumar, MD of UC Irvine Health Chao Family gives an update on Acute Myeloid Leukemia at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Angela Fleischman, MD, PhD of University of California, Irvine discusses Mutational Landscape of MPN; Emerging JAK Inhibitors; Ruxolitinib Combination Trials; Anti-Fibrotic Agents at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Monica El-Masry, MD & Bhavana Pathak, MD present Cardiovascular Disease in Adolescents and Young Adults with Hematologic Malignancies at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Eric Van Cutsem, MD of University of Leuven discusses the RECOURSE trial design and its primary endpoint results at ASCO Gi 2016

Eric Van Cutsem, MD of University of Leuven discusses the risk-benefit ratio for TAS-102 in advanced treatment refractory colorectal cancer at ASCO GI 2016

Eric Van Cutsem, MD of University of Leuven discusses a subgroup analysis of the RECOURSE trial and new information regarding TAS-102 and its effects at ASCO GI 2016         clinical trial, received tas-102, tas-102

Eric Van Cutsem, MD of University of Leuven discusses the TAS-102 mechanism of action and potential toxicity in advanced CRC

Eric Van Cutsem, MD of University of Leuven discusses the therapeutic algorithm for TAS-102 in metastatic colorectal cancer at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the design of the RECOURSE trial on which the FDA approved TAS-102 at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the performance status of patients in the RECOURSE trial at ASCCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the biggest questions facing the treatment of colorectal cancer at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses how has the last 10 years changed the way you treat metastatic colorectal cancer

Axel Grothey, MD of Mayo Clinic discusses immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses key trials that will move treatment forward in colorectal cancer at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses why more money should be allocated to early detection and screening in colorectal cancer at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses potential cases to use Regorafenib over TAS-102 ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses regorafenib experience and integrating TAS-102 for advanced CRC at ASCO GI 2016

Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses pembrolizumab and more value in squamous cell carcinomas or adenocarcinomas ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses using TAS-102 after initial therapy with regorafenib at ASCO Gi 2016

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of isatuximab (SAR650984) for the treatment of relapsed/refractory multiple myeloma (MM). Isatuximab is an anti-CD38 monoclonal antibody, that is very well tolerated by MM patients, with a response rate of 20-29% based on different cohorts. This drug is now being taken into a larger Phase II trial with over 100 patients taking one single dose of isatuximab. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc…

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann, BSc, MD, FRCP, from UCL Cancer Institute and UCL Hospitals, London UK, explains that oncologists and other clinical staff, who possess highly technical expertise in the management of cancer, can have an important role in providing genetic counselling for patients diagnosed with ovarian cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain provides an overview of the SIRIUS clinical trial of daratumumab, an anti-CD38 monoclonal antibody, in the treatment of relapsed/refractory multiple myeloma (MM) patients. Approximately 100 patients received daratumumab as a single-agent, and 30% of these responded to daratumumab. Dr Mateos discusses the importance of these results, as currently treatment for this patient population is an unmet need. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain discusses the importance of identifying frail/elderly patients using well-establish tools, such as geriatric scales (clinical frailty scales). Dr Mateos also dicusses the available treatment options for this population, such as oral combinations with checkpoint inhibitors and monoclonal antibodies. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the highlights in the field of multiple myeloma (MM), presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. Prof. Landgren focuses on 3 drugs approved by the US Food and Drug Administration (FDA) in November, 2015, two monoclonal antibodies (daratumumab and elotuzumab), and the oral proteosome inhibitor ixazomib. Prof. Landgren also talks about the many combination therapies being presented at ASH 2015, involving three drugs allowing for longer progression free survival (PFS) and overall survival (OS) in MM patients. Another…

Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about biomarkers of cardiotoxicity in multiple myeloma in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.

Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about cardio-oncology in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD, from Institut Gustave Roussy, Villejuif, France, summarises the recent progress in the management of patients with castration-resistant prostate cancer. In addition to an improvement in patient care, there have been improvements in imaging procedures as well as the pathological and molecular understanding of prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses why MSI-high cancers are more responsive to immune checkpoint inhibitors at ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how the STEAM trial may not change treatment paradigm for metastatic CRC at ASCO 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses RAS mutation in patients with metastatic colorectal cancer at ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers at ASCO Gi 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses PD-L1 markers in MMR deficient cancers at ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses mutational load of colorectal and non-colorectal cancers may benefit significantly from immunotherapy.at ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses Mismatch Repair (MMR) deficient and the use of PD-1 blockade at ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses the MAVERICC Phase II study results at ASCO GI 2016

David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how ERCC1 not a valid prognostic or predictive factor in advanced CRC at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses TAS-102 versus 5-flourouracil and other more familiar agents at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses TAS-102 Adverse events compared to other approved flouropyrmidines at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses RECOURSE trial and if performance status impact benefit from TAS-102 at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses the primary and secondary endpoints of the RECOURSE trial for which TAS-102 was approved at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses the importance of performance status prior to starting regorafenib at ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses which EGFR inhibitor to use in second line treatment of mCRC patients at ASCO GI 2016

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses phase 3 clinical trials of atezolizumab, an anti-PD-L1 monoclonal antibody, compared with standard chemotherapy in PD-L1-selected chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from LUX-lung 7, a randomised, open-label, phase 2b trial comparing afatinib to gefitinib in the first-line treatment setting with patients who are having epidermal growth factor receptor (EGFR) mutation-positive advanced adenocarcinoma of the lung. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from KEYNOTE-010, a phase 2/3 study of pembrolizumab, anti-PD-1 antibody, versus docetaxel for patients with PD-L1-positive non-small cell lung cancer (NSCLC) who had disease progression after platinum-containing systemic therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the clinical development of AZD9291, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of patients with EGFR T790M-mutant non-small cell lung cancer (NSCLC) following resistance to frontline anti-EGFR therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL, and how these impact the treatment landscape in chronic lymphocytic leukemia (CLL).

Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses associated with long-term therapies in chronica lymphocytic leukemia (CLL). At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL, data on several new therapies was presented, which indicates a new era for CLL, where patients will be treated for longer periods of time, potentially lasting several years. This raises financial and political issues that are being discussed in the CLL community, with clinicians and advocates pushing for the development of finite therapies that can achieve complete remission or minimum residual disease (MRD) negativity.

Michael Hallek, MD from the University of Cologne, Cologne, Germany, provides an overview of main chronic lymphocytic leukemia (CLL) studies being presented at the America Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. Prof. Hallek discusses the new data being presented on venetoclax (ABT-199), a Bcl-2 inhibitor, in CLL patient with 17p deletion or mutated p53, and inhibitors targeting well-known CLL targets, such as Bruton’s tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K), as single-agents or in combinations with other therapies.

Andrew Davies, MD, BSc, MRCP, PhD, from the University of Southampton, Southampton, UK provides an overview of the REMoDL-B clinical trial, a Phase III study for untreated diffuse large B-cell lymphoma patients. The aims of this study were to compare R-CHOP plus bortezomib to R-CHOP alone, as front-line therapy. The trial also aimed to develop a gene expression profiling test to determine the genetic sub-type (ABC or GCB), and if the different sub-types would have an increased benefit from the addition of bortezomib therapy.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the results to date of LUX-Lung 7, a global, randomised, open-label, phase 2b clinical trial comparing afatinib, an irreversible ErbB family blocker, to gefitinib for the first-line treatment of patients who have epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the application of the concept oncogene addiction, which postulates that a cancer cell exhibits dependence on a single oncogenic pathway or protein for its sustained proliferation or survival, in the development of targeted therapies for non-small cell lung cancer (NSCLC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Daniel Catenacci, MD of The University of Chicago Medicine discusses weekly T-DM1 surprising or disappointing at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses the ToGA trial and how it changed the management of HER2+ gastric carcinoma at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses post-operative adjuvant therapy for resectable patients with node positive esophageal cancer at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses the NEOSCOPE trial results and management of resectable esophageal adenocarcinoma at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses why the NEOSCOPE trial may not be significantly and clinically meaningful at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept adding anti-angiogenic agent to chemotherapy in advanced gastric adenocarcinoma at ASCO GI 2016

The Role of PD-L1 Pathway in Cancer Immune Invasion

The Importance of PD-L1 Expressions on Tumor and Immune Cells

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Peter Van Loo, PhD, from The Francis Crick Institute, London, UK, discusses the aims of his research group, which include understanding the genes involved in tumour evolution and developing “molecular archaeology” approaches that use genomic information to create detailed timelines of cancer development across many different cancer types. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Howard S Hochster, MD of Yale Medical Center discusses adverse event profile for TAS-102 at ASCO GI 2016

Howard S Hochster, MD of Yale Medical Center discusses the future of TAS-102 and regorafenib for patients with colorectal cancer at ASCO GI 2016

Howard S Hochster, MD of Yale Medical Center discusses Phase III RECOURSE trial on which FDA approval for TAS-102 was based at ASCO Gi 2016

Howard S Hochster, MD of Yale Medical Center discusses RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib at ASCO GI 2016

Howard S Hochster, MD of Yale Medical Center discusses TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1 at ASCO GI 2016

Davendra Sohal, MD of Cleveland Clinic discusses the reason microsatellite instability responds to immunotherapy in colon cancer at ASCO GI 2016

Davendra Sohal, MD of Cleveland Clinic discusses Pancreatic Cancer News from ASCO GI 2016

Davendra Sohal, MD of Cleveland Clinic discusses promise in MSI-High Colorectal Cancer at ASCO GI 2016

Davendra Sohal, MD of Cleveland Clinic discusses the highlights from ASCO GI 2016

Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab more value in squamous cell carcinomas or adenocarcinomas at ASCO GI 2016

Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab looks promising according to KEYNOTE-028 results at ASCO GI 2016

Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses clinical trial efforts in UGI cancers with the anti-PD-1 and PD-L1 monoclonal antibodies at ASCO GI 2016

Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses the next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies at ASCO GI 2016

Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses KEYNOTE-028 results with pembrolizuma at ASCO GI 2016

Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses Checkmate-032 trial and the results presented in UGI cancers at ASCO GI 2016

Al B Benson, MD of Northwestern University explains TAS-102 at ASCO GI 2016

Al B Benson, MD of Northwestern University discusses the optimal dosage using Regorafinib in colorectal cancer at ASCO GI 2016

Al B Benson, MD of Northwestern University discusses managing patients on regorafenib including adverse events at ASCO GI 2016

Joel Randolph Hecht, MD of UCLA Health discusses T-DM1 trial results, surprising or disappointing? from ASCO GI 2016

Joel Randolph Hecht, MD of UCLA Health discusses phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016

Joel Randolph Hecht, MD of UCLA Health discusses how did the ToGA trial changed the management of HER2+ gastric carcinoma at ASCO GI 2016

Joel Randolph Hecht, MD of UCLA Health discusses FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without bevacizumab at ASCO GI 2016

Joel Randolph Hecht, MD of UCLA Health discusses ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma at ASCO GI 2016

Joel Randolph Hecht, MD of UCLA Health discusses antiangiogenic agents in advanced esophagogastric adenocarcinomas at ASCO GI 2016

Manish Shah, MD of Weill-Cornell Medical Center states that the future of gastric cancers will be targeted agents including immunotherapy at ASCO GI 2016

Manish Shah, MD of Weill-Cornell Medical Center discusses the standard of care for good performance status patients with advanced gastric adenocarcinomas at ASCO GI 2016

Manish Shah, MD of Weill-Cornell Medical Center discusses the phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma at ASCO GI 2016

Manish Shah, MD of Weill-Cornell Medical Center, NYC discusses FOLFIRI versus FOLFOX7 will this randomized trial advance the treatment paradigms for advanced gastric cancer at ASCO GI 2016

Manish Shah, MD of Weill-Cornell Medical Center, NYC answers the question does the Asian population differ from the western populations in regards to gastric cancers at ASCO GI 2016

What direction is research taking in the field of myeloproliferative neoplasms (MPNs)? Dr. Laura Michaelis of Medical College of Wisconsin supplies an overview of MPN therapies, both those currently in use and those still in development. Dr. Michaelis begins with JAK inhibitors and works her way through layers and iterations of newer, more innovative treatments, covering several new categories. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) conference, Andrew spends a few minutes with myeloma expert Dr. Stephen Nimer from the University of Miami Health System, discussing the role of epigenetics and immunotherapy as the newest line of defense against cancer. Dr. Nimer gives a short primer on epigenetics and then explains the biology behind its ability to re-educate cancer cells. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Robert West, PhD, from University College London, London, UK, discusses data from monthly national surveys in adults in England on the use of electronic cigarettes (e-cigarettes) and its relationship with smoking uptake and smoking cessation. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Sergio Quezada, PhD, from University College London, London, UK, discusses emerging immunotherapeutic approaches for treating various cancer types. The improved understanding of the underlying principles of cancer biology and immunology, including the mechanisms of checkpoint signalling pathways and actions of immunomodulators, have been an important advance in immunotherapeutic agent development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. William Wierda of MD Anderson Cancer Center shares his insights on the tornado of research activity out of ASH 2015 meeting (American Society of Hematology) and perspective on the latest news and research in the field of CLL. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient Power founder, Andrew Schorr, caught up with CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology (ASH) meeting to hear his perspective on CLL news from the conference. Dr. Kipps is enthusiastic about the possible use of combination therapy: We might be able to truly affect a cure for this disease! Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Michael Keating, from MD Anderson Cancer Center, joins us for another segment in our Ask The Expert series, answering a question about the potential combination of obinutuzamab (Gazyva) and ABT-199 (Venetoclax) and whether this is a treatment approach that could be effective and safe. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Andrew Zelenetz of Memorial Sloan Kettering Cancer Center describes the expanding CLL and lymphoma armamentarium on location at the 2015 American Society of Hematology (ASH). Dr. Zelenetz and Carol Preston discuss the results of an international studydesigned to improve the current standard of carethat is now leading to a wealth of treatment choices. Says Dr. Zelenetz, We have the tools now to treat CLL in such a way that we can get deep remissions. Sponsored by the Patient Empowerment Network through educational grants from Teva and Pharmacyclics. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on…

CLL experts Drs. Zeev Estrov, Nicole Lamanna and Michael Keating at our town meeting at MD Anderson Cancer Center in Houston, Texas, discussed the various symptoms related to CLL. The physicians follow up the discussion answering the questions, How does CLL progress, and when should treatment begin? Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Claire Harrison, Hematologist at Guy and St. Thomas Hospital, covers the myeloproliferative neoplasm (MPN) highlights including drug and basic science research. Listen as she mentions key studies, both new for 2016 and ongoing with updated information. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Elaine Vickers, PhD, Founder and Principal Trainer of Science Communicated, Sheffield, UK, discusses her workshops that aim to explain the scientific concepts, including the molecular and cellular basis of cancer and their clinical application, behind the plenary lectures at the conference. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer at ASCO GU 2016

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers at ASCO GU 2016

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab at ASCO GU 2016

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer at ASCO GU 2016

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer at ASCO GU 2016

Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, provides an overview if the Phase III clinical trial of ibrutinib vs chlorambucil in chronic lymphocytic leukemia (CLL) patients over the age of 65. Progression free survival (PFS) and overall survival (OS) were increased in the ibrutinib arm, demonstrating the superior efficacy of this drug over chlorambucil.

Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the current treatment landscape in chronic lymphocytic leukemia (CLL), considering the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting.

Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the impact of the clinical trial of venetoclax (ABT-199) with obinutuzumab in the treatment landscape chronic lymphocytic leukemia (CLL).

Thomas J Kipps, MD from the University of California, San Diego, CA, provides an overview of the clinical trial RESONATE-2 comparing ibrutinib with chlorambucil in chronic lymphocytic leukemia (CLL) patients not suitable to receive standard chemotehrapy. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, that targets B-cells and causes them to leave the lymph nodes and bone marrow. This drug has been shown to be effective in the treatment of CLL and therefore it has been approved in relapsed disease as a single-agent. Patients in the ibrutinib arm had a longer progression free survival (PFS), and survival advantage over chlorambucil.

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib. Prof. Dyer also discusses

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, discusses the importance of targeting proliferanting and quiescent chronic lymphocytic leukemia (CLL) cells. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the importance of Bcl-2-targeted therapies. They discuss recent sucesses of Bcl-2 targeting drugs, such as venetoclax (ABT-196) in the field of chronic lymphocytic leukemia.

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the recent developments occuring in CLL and how certain molecules such as Bcl-2, BTK and PI3K, have moved from being biomarkers and stratification markers to becoming targets of the disease.

Barbara Eichhorst, MD from the Ludwig-Maximilians University, Munich, Germany, provides an overview of combination studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting held in Orlando, FL. Dr Eichhorst gives an overview of the Phase III clinical trial comparing chlorambucil with ibrutinib as front-line therapies, and an overview of the Phase II clinical trial of venetoclax in chronic lymphocytic leukaemia (CLL) patients with 17p deletion.

At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL., Dr Naval Daver from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of new combination therapies involving hypomethylating agents. Dr Daver focuses on the following combinations: decitabine and vosarocin; decitabine and venetoclax (ABT-199); cytarabine and SGN-CD33A a CD33a monoclonal antibody .

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer at ASCO 2016.

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses ongoing clinical trials that will establish a clinical role for molecular risk factors in prostate cancer at ASCO GU 2016.

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer at ASCO GU 2016

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers have greater impact on risk of recurrence than cancer stage and PSA levels at ASCO GU 2016

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses Genetic Testing in Prostate Cancer at ASCO GU 2016

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses using new therapies earlier in prostate cancer may returns better results from ASCO GU 2016

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses significant off-target adverse events from novel treatments directed at molecular targets in CRPC at ASCO GU 2016

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses resistance to CYP17 and AR inhibitors such as the AR-7 Splice Variant in prostate cancer at ASCO GU 2016 in San Francisco.

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses new recently discovered novel targets for CCRPC at ASCO GU 2016 in San Francisco.

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses galeterone and alternative splicing does this agent differ from approved agents such as abiraterone and enzalutamide at ASCO GU 2016 in San francisco.

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses the agents currently available or in research pipelines than target molecular abnormalities in CRPC at ASCO GU 2016 in San Francisco.

Tam Constantine, MD from Peter MacCallum Cancer Centre & St. Vincent’s Hospital Melbourne, Melbourne, Australia, gives an overview of the new data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on BGB-3111, a second generation Bruton’s tyrosine kinase (BTK) inhibitor. The data presented were obtained from a Phase I clinical trial, where the drug was well tolerated and demonstrated a good safety profile.

Eileen Kaner, MSc, PhD, Hon FRCP gives an overview of a session focusing lifestyle behaviour and cancer prevention presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. The session outlines current epidemiological and behavioural evidence on the relationship between different lifestyle choices and the development of cancer. The session hosted talks by Paolo Boffetta, Peter Anderson and Martin Wiseman, and focused on diet, exercise and alcohol consumption.

Alan Burnett, MD from Cardiff University, Cardiff, UK discusses the new technology developments in the field of acute myeloid leukemia (AML), at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. He primarily discusses the use of genomic testing to provide a more accurate prognosis with conventional treatment, and the development of companion diagnostics (i.e. gene signatures that can help predict a response to a particular treatment). Other technologies discussed are the improvements on flow cytometry and its use in disease monitoring, in particular, we can now have a closer look at minimal residual disease. On the…

Dr Naughton communicates the clinical actionability of a Low Risk/Low Likelihood of Benefit BCI result in his practice.

What is CLL? How and where does it start? CLL experts Dr. Nicole Lamanna of Columbia University Medical Center and Dr. Michael Keating of MD Anderson Cancer Center answer these questions, offering a clear and basic definition. Listen for Dr. Keating to share his insight about a possible future CLL vaccine. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

From our Ask the Expert series, CLL expert Dr. Michael Keating of MD Anderson Cancer Center answers a common CLL question: Do inhibitor treatments have to be a lifelong medicine? Listen as Dr. Keating describes his personal disinclination for what he refers to as just controlling the disease and how he anticipates immunotherapy strategies being used to eventually eradicate CLL. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Michael Keating of MD Anderson Cancer Center answers the question: Does CLL return more aggressively after relapse than it was initially? Listen as Dr. Keating explores the tendencies of recurring CLL, including WBC doubling time and indolence. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Toni Choueiri, MD of Dana Farber gives us Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium from San Francisco

Dr. Toni Choueiri, MD of Dana Farber gives an ASCO GU 2016 Update on Clear Cell and non-Clear Cell Renal Carcinomas from San Francisco.

Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses how Avelumab is tolerable for patients according to JAVELIN Solid Tumor phase Ib trial at ASCO GU 2016.

Dr. Andrea B. Apolo, MD from the National Cancer Institute discusses the next steps and moving Checkpoint Inhibitors from metastatic advanced setting to earlier disease states in urothelial cancers. ASCO GU 2016 in San Francisco

Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. at ASCO GU 2016 in San Francisco.

Dr. Nima Sharifi, MD of Cleveland Clinic comments on how investigators are now looking to use new therapies earlier within prostate cancer disease states which may be more effective from ASCO GU 2016.

Dr. Nima Sharifi, MD at Cleveland Clinic gives an overview of his presentation Androgen Receptor New Ways of Targeting the Old Target at ASCO Gu 2016 in San Francisco

Dr. Nima Sharifi, MD at Cleveland Clinic discusses the ALLIANCE trial and the combinations of CYP17 and AR inhibitors in CRPC at ASCO GU 2016 in San francisco

Dr. Nima Sharifi, MD of Cleveland Clinic discusses the potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer at ASCO GU 2016 in San Francisco.

Dr. Nima Sharifi, MD of Cleveland Clinic answers the question How does CYP17 inhibitors and novel androgen receptor inhibitors affect current treatment paradigms for advanced prostate cancer at ASCO GU 2016 in San Francisco.

Nima Sharifi, MD of Cleveland Clinic discusses the new Androgen Receptor Signaling and the new targets and agents for advanced prostate cancer at ASCO GU 2016 in San Francisco.

Dr. Petros Grivas, MD at Cleveland Clinic discusses the correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC) at ASCO GU 2016

Dr. Petros Grivas, MD at Cleveland Clinic discusses atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) at ASCO GU 2016 in San Francisco.

Dr. Petros Grivas, MD at Cleveland Clinic discusses the evaluation of response to enzalutamide consecutively after disease progression on abiraterone prednisone at ASCO GU 2016 in San Francisco.

Dr. Petros Grivas, MD of Cleveland Clinic discusses The association of D4, 3-keto-abi (D4A) and response to abiraterone in castration-resistant prostate cancer (CRPC) from ASCO GU 2016.

Dr. Walter Stadler of The University of Chicago Cancer Center @UCCancerCenter discusses Choosing predictive markers for PD-1 and PD-L1 inhibitors in RCC at ASCO GU 2016

“Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and acalabrutinib (ACP-196), target chronic lymphocytic leukaemia (CLL) cells and the common side-effects experienced by these drugs. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.”

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of venetoclax (ABT-199) for the treatment of chronic lymphocytic leukemia (CLL), as a single-agent and in combination with other therapies. Peter Hillmen discusses two studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting. These clinical trials study the use of venetoclax with rituximab and venetoclax with obinutuzumab.

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of the Resonate-2 clinical trial of ibrutinib vs. chlorambucil as front-line therapy, in patients unfit for fludarabine, cyclophosphamide, rituximab (FCR) therapy. The Phase III results presented at the American Society of Hematology (ASH) 2015 Annual Meeting, show that 98% of patients in the ibrutinib arm have a progression free survival period longer than 2 years.

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase Ib study of venetoclax (ABT-199) and obinutuzumab, an anti-CD20 antibody, in relapsed/refractory or previously untreated chronic lymphocytic leukaemia (CLL). The preliminary data show patients achieving minimum residual disease (MRD) states with no toxicity.

Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 96% of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.

Jacqueline Barrientos, MD, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data suggest that this may achieve minimum residual disease (MRD) negativity with a low risk of side effects.

Jacqueline Barrientos, MD, discusses the importance of understanding treatment failure in CLL patients, and what options are available. She provides details of a current trial comparing two treatments that work on different pathways (PI3K and BTK B-cell inhibitors), with the goal of understanding the best salvage options following treatment failure.

Jacqueline Barrientos, MD, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that had no post-trial access to ibrutinib, or those who moved to a comparator. The insights from this study help to inform decisions regarding sequential and salvage treatments.

Dr. Walter Stadler of the University of Chicago discusses how Checkpoint inhibitors iwill mpact outcomes for advanced RCC

Dr. Walter Stadler discusses his experience with FDA approved Nivolumab and PD-1 and PD-L1 inhibitors in RCC

Patient Power founder Andrew Schorr along with patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) meeting sit down with Dr. Jennifer Cultrera to discuss the progress in treating follicular lymphomas. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

How far have we progressed in the field of CLL research? Patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) meeting, visited with leading CLL expert Dr. Richard Furman to hear his perspective on news from the conference. Listen as Dr. Furman gives a rundown of last years novel agents and todays best possibility for deep remission. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Is there hope for people with Hodgkin Lymphoma? Dr. John Sweetenham, Executive Medical Director of the Huntsman Cancer Institute, says, Yes! On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) conference, Andrew Schorr visits with Dr. Sweetenham to discuss emerging agents and monitoring strategies for patients with Hodgkin lymphoma. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Are clinical trials still valid as a means for treatment? On location at the 2015 American Society of Hematology (ASH), Medical Correspondent, Carol Preston, speaks with myeloma expert Dr. Sagar Lonial, Chief Medical Officer at Winship Cancer Institute of Emory University, about the rapidly changing therapies for multiple myeloma patients. Listen as Dr. Lonial makes a strong statement for clinical trials as the catalyst for a cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma.

Watch patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) conference, discusses the new molecule, ACP-196, a second-generation BTK inhibitor, with CLL expert Dr. Kathryn Kolibaba. Dr. Kolibaba describes this new molecules function including its potential for decreased side effects and her hopes for the future. Never, exclaims Dr. Kolibaba, have we had a better menu of options. Never have we had hope like we do now for a cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

As part of our coverage of the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naveen Pemmaraju from MD Anderson Cancer Center joined Patient Power to discuss social media and hematology, focusing on a well-attended session from the meeting. Dr. Pemmaraju expands on the benefits of using social media to educate patients as well as potential issues with this form of communication. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Lymphoma expert Dr. Jeff Sharman, on location at 2015 American Society of Hematology (ASH) meeting, reviews the advancement of follicular lymphomas (non-Hodgkin lymphomas) as they rapidly progress towards becoming a chronic condition. Watch as Dr. Sharman extends hope to patients through use and understanding of clinical trials. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2015 American Society of Hematology (ASH) conference, patient advocate Carol Preston and Dr. Christopher Yasenchak, from US Oncology Research, discuss encouraging news for Hodgkin lymphoma patients who are over 60 years old. Dr. Yasenchak explains why 50 percent of older patients cannot tolerate current potent chemo side effects and the exciting new combination treatments in pre-clinical trial that offer, as Dr. Yasenchak says a game-changing opportunity. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Endocrine therapy may cause many bothersome side effects, often affecting a patients compliance. Dr Naughton suggests BCI as a tool to objectively help patients understand their likelihood of benefit and help encourage them to continue therapy, if appropriate. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Is there current research for the 20 percent of CML (Chronic Myelogenous Leukemia) patients who are resistant to imatinib mesylate (Gleevec)? CML expert Dr. Kathryn Kolibaba answers with an emphatic Yes!. Patient advocate Carol Preston speaks with Dr. Kolibaba as they discuss various studies directed at improving quality of life and managing Gleevec-resistant patients. The data is very, very promising, reports Dr. Kolibaba. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient Power founder caught up with leading CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology (ASH) meeting to hear his perspective on CLL news from the conference. Watch as Dr. Kipps reviews data, including the use of ibrutinib (Imbruvica) in the frontline setting, the role of chemotherapy and an update on emerging therapies. Sponsored by the Patient Empowerment Network through educational grants from Teva and Pharmacyclics. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Are clinical trials still a good idea for patients? Is there still a place for chemo? Who should get genetic testing and when should it be done? Dr. Nicole Lamanna, Associate Clinical Professor of Medicine at Columbia University Medical Center answers in-depth questions about CLL on location in Orlando, Florida at the 2015 American Society of Hematology (ASH). Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2015 American Society of Hematology (ASH) annual meeting, myeloma expert Dr. James Berenson joined Patient Power to discuss the recent wave of approvals for the treatment of multiple myeloma. Dr. Berenson speaks about the range of new therapies, discussing monoclonal antibodies, proteasome inhibitors and many others, including where each of these treatments fit into patient care. He also discusses potential issues with patient compliance, the cost of treatment and the path to cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

What is the REVEAL study, and why is it so important to polycythemia vera (PV) patients? On location at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Brady Stein from Robert H. Lurie Comprehensive Cancer Center discusses the demographics and benefits of the study. Dr. Stein is particularly hopeful with the new developments and sophisticated prognosis being applied to PV. You can learn more about the REVEAL study at revealpvstudy.com. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo